Michael Jelinek to Lung Neoplasms
This is a "connection" page, showing publications Michael Jelinek has written about Lung Neoplasms.
Connection Strength
1.089
-
Adjuvant Osimertinib: A New Standard of Care. Oncologist. 2021 04; 26(4):263-265.
Score: 0.501
-
Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy. Clin Lung Cancer. 2019 11; 20(6):e597-e600.
Score: 0.457
-
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
Score: 0.131